First-line treatment with sulfonylureas instead of metformin in people with type 2 diabetes is associated with a significantly elevated risk of death, according to results from an observational study presented at the European Association for the Study of Diabetes (EASD) meeting in Barcelona. Although guidelines do not recommend the use of sulfonylureas for first-line treatment, the drugs are…
Increase In Deaths Linked To First Line Treatment With Sulfonylureas
September 25, 2013 by Leave a Comment
Top Line Results: No Cardiovascular Benefits Found For Saxagliptin
June 19, 2013 by Leave a Comment
Top line results of a large phase 4 study with saxagliptin (Onglyza, Bristol-Myers Squibb and AstraZeneca) demonstrate that the drug is safe but has no cardiovascular benefits. AstraZeneca and Bristol-Myers Squibb today announced the top line results for the SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza®. The full results are scheduled to presented at the annual meeting of the European Society of Cardiology in Amsterdam on…
Recent Comments